FOLH1 and prostate carcinoma: In our effort to develop theranostic agents of the same molecule with diagnosis and therapy properties, we evaluated our first multi-dentate agent based on PSMA binding, 18F-MD-PSMA, in humans (NCT03507595), designed to demonstrate its performance of PET/CT in men with prostate cancer BCR.